These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 17699257

  • 21. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS, Kadiyala A, Gill J, Bunnapradist S.
    Transplantation; 2009 Oct 15; 88(7):904-10. PubMed ID: 19935462
    [Abstract] [Full Text] [Related]

  • 22. Immunoexpression of perforin and granzyme B on infiltrating lymphocytes in human renal acute allograft rejection.
    Wagrowska-Danilewicz M, Danilewicz M.
    Nefrologia; 2003 Oct 15; 23(6):538-44. PubMed ID: 15002789
    [Abstract] [Full Text] [Related]

  • 23. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.
    Villanueva ME, Muñoz AS, Casasola CC, Africa JB, Danguilan RA, Ona ET.
    Transplant Proc; 2008 Sep 15; 40(7):2222-5. PubMed ID: 18790198
    [Abstract] [Full Text] [Related]

  • 24. Foxp3 staining in BK virus allograft nephropathy and comparison with acute cellular rejection.
    Miller DC, Qazi Y, Smogorzewski M, Azen CG, Shah T, Koss MN.
    Transplant Proc; 2009 Dec 15; 41(10):4188-92. PubMed ID: 20005366
    [Abstract] [Full Text] [Related]

  • 25. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
    Kirsch BM, Haidinger M, Zeyda M, Böhmig GA, Tombinsky J, Mühlbacher F, Watschinger B, Hörl WH, Säemann MD.
    Transpl Immunol; 2006 Nov 15; 16(3-4):254-7. PubMed ID: 17138063
    [Abstract] [Full Text] [Related]

  • 26. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.
    Garcia M, Weppler D, Mittal N, Nishida S, Kato T, Tzakis A, Ruiz P.
    Transplant Proc; 2004 Mar 15; 36(2):323-4. PubMed ID: 15050146
    [Abstract] [Full Text] [Related]

  • 27. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G, Slavin S, Goldman JM, Mackinnon S, Giralt S, Waldmann H.
    Bone Marrow Transplant; 2002 Dec 15; 30(12):797-804. PubMed ID: 12476271
    [Abstract] [Full Text] [Related]

  • 28. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
    Sundberg AK, Roskopf JA, Hartmann EL, Farney AC, Rohr MS, Stratta RJ.
    Transplant Proc; 2005 Mar 15; 37(2):1294-6. PubMed ID: 15848701
    [Abstract] [Full Text] [Related]

  • 29. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N, Toit C, Abrahams L, Thomas V, Bunjes D, Duncker C, Wiesneth M, Selleslag D, Hidajat M, Starobinski M, Bird P, Waldmann H.
    Bone Marrow Transplant; 2000 Jul 15; 26(1):69-76. PubMed ID: 10918407
    [Abstract] [Full Text] [Related]

  • 30. CD3+-mediated rejection and C4d deposition in two composite tissue (bilateral hand) allograft recipients after induction with alemtuzumab.
    Landin L, Cavadas PC, Ibañez J, Roger I, Vera-Sempere F.
    Transplantation; 2009 Mar 15; 87(5):776-81. PubMed ID: 19295326
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: a meta-analysis.
    Shou ZF, Zhou Q, Cai JR, Cheng J, He Q, Wu JY, Chen JH.
    Chin Med J (Engl); 2009 Jul 20; 122(14):1692-8. PubMed ID: 19719973
    [Abstract] [Full Text] [Related]

  • 32. Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China.
    Yuan-Xin L, Ning L, You-Sheng L, Xiao-Dong N, Ming L, Jian W, Jie-Shou L.
    Transplant Proc; 2010 Jul 20; 42(1):29-34. PubMed ID: 20172275
    [Abstract] [Full Text] [Related]

  • 33. Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion.
    Silveira FP, Marcos A, Kwak EJ, Husain S, Shapiro R, Thai N, McCurry KR, Abu-Elmagd K, Paterson DL.
    J Infect; 2006 Oct 20; 53(4):241-7. PubMed ID: 16403576
    [Abstract] [Full Text] [Related]

  • 34. Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses.
    Anderson AE, Lorenzi AR, Pratt A, Wooldridge T, Diboll J, Hilkens CM, Isaacs JD.
    Rheumatology (Oxford); 2012 Aug 20; 51(8):1397-406. PubMed ID: 22447884
    [Abstract] [Full Text] [Related]

  • 35. The presence of B-cell nodules does not necessarily portend a less favorable outcome to therapy in patients with acute cellular rejection of a renal allograft.
    Doria C, di Francesco F, Ramirez CB, Frank A, Iaria M, Francos G, Marino IR, Farber JL.
    Transplant Proc; 2006 Dec 20; 38(10):3441-4. PubMed ID: 17175297
    [Abstract] [Full Text] [Related]

  • 36. Reversal of acute cellular rejection after renal transplantation with Campath-1H.
    Basu A, Ramkumar M, Tan HP, Khan A, McCauley J, Marcos A, Fung JJ, Starzl TE, Shapiro R.
    Transplant Proc; 2005 Mar 20; 37(2):923-6. PubMed ID: 15848576
    [Abstract] [Full Text] [Related]

  • 37. Campath-1H use in pediatric renal transplantation.
    Bartosh SM, Knechtle SJ, Sollinger HW.
    Am J Transplant; 2005 Jun 20; 5(6):1569-73. PubMed ID: 15888071
    [Abstract] [Full Text] [Related]

  • 38. Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation.
    Clatworthy MR, Sivaprakasam R, Butler AJ, Watson CJ.
    Transplantation; 2007 Dec 27; 84(12):1563-7. PubMed ID: 18165765
    [Abstract] [Full Text] [Related]

  • 39. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
    Schadde E, D'Alessandro AM, Knechtle SJ, Odorico J, Becker Y, Pirsch J, Sollinger H, Fernandez LA.
    Transpl Int; 2008 Jul 27; 21(7):625-36. PubMed ID: 18397178
    [Abstract] [Full Text] [Related]

  • 40. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).
    Walsh M, Chaudhry A, Jayne D.
    Ann Rheum Dis; 2008 Sep 27; 67(9):1322-7. PubMed ID: 18055469
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.